Prof Martin Hoyle is a Professor of Health Innovation and Evaluation at the Macquarie University Centre for the Health Economy (MUCHE).

He now leads a team of researchers in MUCHE that work on submissions for the Australian Medical Services Advisory Committee (MSAC) and critique pharmaceutical company submissions to the Australian Pharmaceutical Benefits Advisory Committee (PBAC).

Prof Hoyle has evaluated drugs in many clinical areas including various cancers (chronic lymphocytic leukaemia, chronic myeloid leukaemia, multiple myeloma, neuroendocrine tumours, colorectal cancer, gastro-intestinal stromal tumours, renal cell carcinoma, soft tissue sarcoma), chemotherapy-induced anaemia, multiple sclerosis, Alzheimer's disease. Other evaluations include vaccines for influenza, cochlear implants for hearing, diagnostic tests for Lynch Syndrome, tests for pre-term labour in women, influenza vaccines. He has defended Assessment Group reports at 34 UK NICE Appraisal Committee meetings and 11 ESC meetings in Australia.

He has published papers on HTA methodology, specifically on assumptions regarding appropriate patient cohorts to model, assumptions for future drug prices and a method to recreate and analyse individual patient data using only summary survival data.

He was the external examiner for the MSc in Health Economics and Decision Modelling, University of Sheffield, from 2016 to 2018, and was a panel member for the Research for Patient Benefit (RfPB) South West. In 2017-8, he was also an advisor to NICE on implementation of the NICE Fast Track Appraisal (FTA) process, and an advisor to NICE on implementation of the "Adjusted TA" process.

Prior to joining the Centre, Martin was Director of PenTAG (Peninsula Technology Assessment Group) in the Medical School at the University of Exeter, where he performed health technology assessments for the National Institute for Health and Care Excellence (NICE), and the National Institute for Health Research (NIHR) in the United Kingdom. His undergraduate training was in Mathematics at the University of Cambridge.  This accounts for his interest in the mathematics and statistics of HTA.